Trial Profile
A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 04 Jul 2018 Status changed from active, no longer recruiting to completed.
- 01 Sep 2016 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
- 01 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.